An Evaluation of Safety and Feasibility Using Repetitive Transcranial Magnetic Stimulation (rTMS) in Adolescents With Depression

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-05-31

Study Completion Date

2009-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this investigation is to examine the safety and feasibility of a series of repetitive transcranial magnetic stimulation (rTMS) treatments (10 Hertz \[Hz\]; Left Dorsolateral Prefrontal Cortex), with a Neuronetics Model 2100 Therapy System as adjuvant treatment for depression in adolescent subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biomarkers in Repetitive Transcranial Magnetic Stimulation (rTMS) for Adolescent Depression

NCT03363919

Major Depressive Disorder

COMPLETED NA

Study of a Repetitive Transcranial Magnetic Stimulation (rTMS) Device for the Treatment of Major Depressive Disorder

NCT00104611

Major Depressive Disorder

COMPLETED PHASE3

Repetitive Transcranial Magnetic Stimulation for Adolescent Depression: Efficacy, Predictive Biomarkers, and Mechanisms

NCT02611206

Treatment Resistant Depression

COMPLETED NA

Efficacy and Safety of Magnetic Resonance Imaging-guided Repetitive Transcranial Magnetic Stimulation (rTMS) in Adolescents With Depression: A Randomized, Double-Blind, Controlled Pilot Study

NCT07185438

Depression - Major Depressive Disorder

RECRUITING NA

Study of Repetitive Transcranial Magnetic Stimulation (rTMS) as Adjuvant Treatment for Depression

NCT01115699

Depression

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

High frequency rTMS applied to the left dorsolateral prefrontal cortex (L-DLPFC) has been shown to have an antidepressant effect. Initial studies comparing electroconvulsive therapy (ECT) and rTMS suggest that rTMS has been as effective as ECT in treating non-psychotic depression. Given the high degree of ongoing dysfunction in depressed adolescents despite optimization of treatment with antidepressant medications, new concerns regarding suicidal thoughts and behaviors in adolescents treated with antidepressant medications, and the more interventional nature of ECT, the use of rTMS as adjuvant therapy may be of significant clinical benefit. Thus far, research using rTMS to treat depression in adolescents has been limited. The primary aim of this study is to examine the safety and feasibility of using 10 Hz rTMS applied to the left dorsolateral prefrontal cortex (L-DLPFC) as adjuvant treatment for depression in adolescents.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

rTMS Treatment

All subjects will have active rTMS treatment (10Hz, L-DLPFC - 3,000 Stimulations/treatment)

Group Type EXPERIMENTAL

rTMS Treatment

Intervention Type DEVICE

Active rTMS treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

rTMS Treatment

Active rTMS treatment.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Neuronetics Model 2100 Therapy System

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) diagnosis of unipolar major depression without psychosis.
* Current or past history of lack of response to at least two adequate antidepressant trials selective serotonin re-uptake inhibitors (SSRI) operationally defined using the Antidepressant Treatment History Form (ATHF)
* Children's Depression Rating Scale-Revised (CDRS-R) score of 40 or higher at baseline
* At least six weeks of ongoing SSRI therapy at a stable dose.
* SSRI Medications will include:

* Citalopram (Celexa, Cipramil, Emocal, Sepram)
* Escitalopram oxalate (Lexapro, Cipralex, Esertia)
* Fluoxetine (Prozac, Fontex, Seromex, Seronil, Sarafem, Fluctin (EUR))
* Fluvoxamine maleate (Luvox, Faverin)
* Paroxetine (Paxil, Seroxat, Aropax, Deroxat)
* Sertraline (Zoloft, Lustral, Serlain)
* Age 13-18 years.
* Outpatient, inpatient, or partial hospitalization patients.
* Capable of providing informed assent/consent (in addition to parent/guardian consent).

Exclusion Criteria

* Current Diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, mental retardation, pervasive developmental disorder, somatoform disorder, dissociative disorder, posttraumatic stress disorder, obsessive-compulsive disorder, eating disorders, antecedents of autism, and all personality disorders.
* Active substance dependence (except nicotine) in the past 12 months.
* Subjects with a history of head trauma, unprovoked seizure history, seizure disorder, or family history of treatment resistant epilepsy.
* Suspected pregnancy or pregnancy as confirmed by a urine pregnancy test at screening.
* History of failure to respond to ECT.
* Metal in the head (except in the mouth), implanted medication pump, cardiac pacemaker.
* Prior brain surgery.
* Risk for increased intracranial pressure such as brain tumor.
* Unable to obtain motor threshold in the subject or motor threshold too high, such that 120% MT cannot be obtained (i.e. \>84% of device output).
* Significant change or increase in antidepressant medications within the last six weeks.
* Change in psychiatrist, psychologist, or therapist within the last four weeks.
* Suicide attempt within the past three months.
* Any suicide attempt or suicidal intent during the study will terminate involvement in this study.
* Subjects currently on stimulant, antipsychotic, atypical antidepressant or tricyclic antidepressant medications.
* Unstable medical or neurological conditions that may include hematological, infectious (such as Human immunodeficiency virus \[HIV\] positive patients) metabolic, or cardiovascular conditions that may preclude safe participation in trial.
* Subjects undergoing anticoagulant, immune suppressive and 1 or chemotherapy, or those who received any of these therapies \</=3 months before enrollment in the study
* Subjects with intra-cardiac lines

Minimum Eligible Age

13 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes